Buckley Capital’s Views on Liquidia Corp. (LQDA)

Buckley Capital Advisors, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -0.5% (net) in the quarter compared to -7.7% return for iShares Russell 2000 Value Index and -9.5% return for the iShares Russell 2000 Index. In the quarter, Donald Trump’s aggressive tariff plans increased economic uncertainty. Although tariffs directly impact less than 5% of the portfolio, the firm was prepared for this situation. However, the widespread selling of stocks affected it significantly. The firm focuses on the fundamentally strong companies regardless of the economic environment. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its first-quarter 2025 investor letter, Buckley Capital Advisors highlighted stocks such as Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that engages in the development and commercialization of various products for unmet patient needs.  The one-month return of Liquidia Corporation (NASDAQ:LQDA) was 25.46%, and its shares gained 24.56% of their value over the last 52 weeks. On May 7, 2025, Liquidia Corporation (NASDAQ:LQDA) stock closed at $15.53 per share with a market capitalization of $1.326 billion.

Buckley Capital Advisors stated the following regarding Liquidia Corporation (NASDAQ:LQDA) in its Q1 2025 investor letter:

“Liquidia Corporation (NASDAQ:LQDA): Pulmonary arterial hypertension (PAH) is a serious and potentially life-threatening lung disease whose root causes span a wide range, from hereditary factors to underlying cardiovascular health conditions to systemic diseases like HIV and connective tissue disorders. PAH impacts an estimated half a million individuals around the globe, with around 50,000 American patients currently under treatment.

Liquidia Corp (LQDA) developed a product called Yutrepia, which uses treprostinil via a dry powder inhaler to treat PAH and a related disease, pulmonary hypertension associated with interstitial lung disease (PH-ILD). LQDA began the regulatory approval process for Yutrepia in 2020. This caught the attention of United Therapeutics Corp (UTHR), which had a near-monopoly on PAH and PH-ILD treatments. While Liquidia’s Yutrepia was a better product than UTHR’s products, the incumbent was able to delay its launch for years in the court system by alleging patent infringement.”

Liquidia Corporation (NASDAQ:LQDA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held Liquidia Corporation (NASDAQ:LQDA) at the end of the fourth quarter, compared to 28 in the third quarter. While we acknowledge the potential of Liquidia Corporation (NASDAQ:LQDA) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we covered Liquidia Corporation (NASDAQ:LQDA) and shared Jim Cramer’s hidden gems and undervalued stocks you need to know. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.